Risk-adapted procedures for HSCT from alternative donor in children with severe aplastic anaemia

Bone Marrow Transplantation

Volumn 42, Issue SUPPL. 2, 2008, Pages

  Fuhrer M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HLA A ANTIGEN; HLA B ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY;

APLASTIC ANEMIA; CHILD; DONOR SELECTION; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA MATCHING; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DEPLETION; QUALITY OF LIFE; RADIATION DOSE; REVIEW; RISK ASSESSMENT; T CELL DEPLETION; T LYMPHOCYTE; WHOLE BODY RADIATION;

ADULT; ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DONOR SELECTION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVING DONORS; LYMPHOCYTE DEPLETION; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RISK ADJUSTMENT; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 55749106978     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.293     Document Type: Review

References (25)

1. Führer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G et al. Immunosuppressive therapy for aplastic anemia in children: A more severe disease predicts better survival. Blood 2005; 106 2102-2104.
2. Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H et al Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 2000; 96: 2049-2054.
3. Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunsuppressive treatment in the last decade: A report from the European Group for Blood and Marrow Transplantation. Haematologica 2007; 92: 11-18.
4. Kosaka Y, Yagasaki H, Sano K, Kobayashi R, Ayukawa H, Kaneko T et al Prospective multicenter trial comparing repeated immunosuppressive therapy with stem cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood 2008; 111: 1054-1059.
5. Bagby GC, Meyers G. Bone marrow failure as a risk factor for clonal evolution: Prospects for leukemia prevention. Hematology AM Soc Hematol Educ Program 2007; 2007: 40-46.
6. Kobayashi R, Yabe H, Hara J, Morimoto A, Tsuchida M, Mugishima H et al. Preceding immunosuppressive therapy with antithymocyte globulin and cyclosporine increases the incidence of graft rejection in children with aplastic anaemia who underwent allogeneic bone marrow transplantation from HLA-identical siblings. Br J Haematol 2006; 135: 693-696.
7. Deeg HJ, Seidel K, Casper J, Anasetti C, Davies S, Gajewski JL et al Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant 1999; 5: 243-252.
8. Deeg HJ, Amylon MD, Harris RE, Collins R, Beatty PG, Feig S et al. Marrow transplants from unrelated donors for patients with aplastic anemia: Minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001; 7: 208-215.
9. Kojima S, Matsuyama T, Kato S, Kigasawa H, Kobayashi R, Kikuta A et al. Outcome of 153 patients with severe aplastic anemia who received transplants from unrelated donors: The Japan Marrow Donor Program. Blood 2002; 100: 799-803.
10. Viollier R, Socie G, Tichelli A, Bacigalupo A, Korthof ET, Marsh J et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant 2008; 41: 45-50.
11. Yagasaki H, Takahashi Y, Kudo K, Ohashi H, Hama A, Yamamoto T et al Feasibility and results of bone marrow transplantation from an HLA-mismatched unrelated donor for children and young adults with acquired severe aplastic anemia. Int J Hematol 2007; 85: 437-442.
12. Stern M, Passweg J, Locasciulli A, Socie G, Schrezenmeier H, Bekassy AN et al. Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia. Transplantation 2006; 82: 218-226.
13. Schrezenmeier H, Passweg JR, Marsh JCW, Bacigalupo A, Bredeson CN, Bullorsky E et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110: 1397-1400.
14. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565-1577.
15. Passweg JR, Socie G, Hinterberger W, Bacigalupo A, Biggs JC, Camitta BM et al. Bone marrow transplantation for severe aplastic anemia: Has outcome improved? Blood 1997; 90: 858-864.
16. Benesch M, Urban C, Sykora KW, Schwinger W, Zintl F, Lackner H et al Transplantation of highly purified CD34+ progenitor cells from alternative donors in children with refractory severe aplastic anaemia. Br J Haematol 2004; 125: 58-63.
17. Woodard P, Cunningham JM, Benaim E, Chen X, Hale G, Horowitz E et al Effective donor lymphohematopoietic reconstitution after haploidentical CD34+-selected hematopoietic stem cell transplantation in children with refractory severe aplastic anemia. Bone Marrow Transplant 2004; 33: 411-418.
18. Kojima S, Inaba A, Yoshimi A, Takahashi Y, Watanabe N, Kudo K et al Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br J Haematol 2001; 114: 706-711.
19. Vassiliou GS, Webb DKH, Pamphilon D, Knapper S, Veys PA. Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low-dose total body irradiation, cyclophosphamide and campath. Br J Haematol 2001; 114: 701-705.
20. Chan KW, Li CK, Worth LL, Chik KW, Jeha S, Shing MK et al. A fludarabine-based conditioning regimen for severe aplastic anemia. Bone Marrow Transplant 2001; 27: 125-128.
21. Bunin N, Aplenc R, Iannone R, Leahey A, Grupp S, Monos D et al. Unrelated donor bone marrow transplantation for children with severe aplastic anemia: Minimal GvHD and durable engraftment with partial T cell depletion. Bone Marrow Transplant 2005; 35: 369-373.
22. Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socie G, Maury S et al Fludarabine, cyclophosphamide and antithymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: A report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005; 36: 947-950.
23. Eapen M, Ramsay NKC, Mertens AC, Robinson LL, DeFor T, Davies SM. Late outcomes after bone marrow transplant for aplastic anaemia. Br J Haematol 2000; 111: 754-760.
24. Socie G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P et al. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med 1993; 329: 1152-1157.
25. Ades L, Mary J-Y, Robin M, Ferry C, Porcher R, Esperou H et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 2004; 103: 2490-2497.